WO2007041502A3 - Procedes pour la determination de la sensibilite a la therapie cancereuse - Google Patents
Procedes pour la determination de la sensibilite a la therapie cancereuse Download PDFInfo
- Publication number
- WO2007041502A3 WO2007041502A3 PCT/US2006/038451 US2006038451W WO2007041502A3 WO 2007041502 A3 WO2007041502 A3 WO 2007041502A3 US 2006038451 W US2006038451 W US 2006038451W WO 2007041502 A3 WO2007041502 A3 WO 2007041502A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- cancer therapy
- determining responsiveness
- molecular tags
- binding
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Dans certains aspects, la présente invention a trait à des procédés et des compositions pour déterminer si une cellule cancéreuse est susceptible de réagir à un traitement avec un agent activité Her2. De préférence, les procédés de l'invention sont mis en oeuvre à l'aide d'ensembles de composés de liaison ayant des étiquettes moléculaires libérables qui sont spécifiques pour de constituants multiples d'un ou de plusieurs types de dimères. Suite à la liaison, les étiquettes moléculaires sont libérées et séparées du mélange de dosage pour analyse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72270905P | 2005-09-30 | 2005-09-30 | |
US60/722,709 | 2005-09-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007041502A2 WO2007041502A2 (fr) | 2007-04-12 |
WO2007041502A3 true WO2007041502A3 (fr) | 2007-10-25 |
Family
ID=37906799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/038451 WO2007041502A2 (fr) | 2005-09-30 | 2006-09-29 | Procedes pour la determination de la sensibilite a la therapie cancereuse |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007041502A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9110066B2 (en) | 2009-01-15 | 2015-08-18 | Laboratory Corporation Of America Holdings | HER-3 antibodies and methods of use |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
CA2711843C (fr) * | 2007-12-20 | 2018-11-13 | Laboratory Corporation Of America Holdings | Procedes de diagnostic du her-2 |
EP2313780B1 (fr) * | 2008-07-08 | 2015-05-20 | George Mason Research Foundation, Inc. | C-erbb2 phosphorylé en tant que marqueur théranostique prédictif supérieur pour le diagnostic et le traitement du cancer |
EA022884B1 (ru) | 2008-08-15 | 2016-03-31 | Мерримак Фармасьютикалз, Инк. | СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА |
SG177252A1 (en) | 2008-12-01 | 2012-03-29 | Lab Corp America Holdings | METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95 |
DK2544680T3 (en) | 2010-03-11 | 2015-04-27 | Merrimack Pharmaceuticals Inc | USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER |
EP3087394A2 (fr) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050130238A1 (en) * | 2003-04-01 | 2005-06-16 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
-
2006
- 2006-09-29 WO PCT/US2006/038451 patent/WO2007041502A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050130238A1 (en) * | 2003-04-01 | 2005-06-16 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
Non-Patent Citations (1)
Title |
---|
TOVEY ET AL.: "Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer?", CLIN. CANCER RES., vol. 11, no. 13, July 2005 (2005-07-01), pages 4835 - 4842 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9110066B2 (en) | 2009-01-15 | 2015-08-18 | Laboratory Corporation Of America Holdings | HER-3 antibodies and methods of use |
Also Published As
Publication number | Publication date |
---|---|
WO2007041502A2 (fr) | 2007-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007041502A3 (fr) | Procedes pour la determination de la sensibilite a la therapie cancereuse | |
WO2009005809A3 (fr) | Compositions et procédés de traitement et de diagnostic d'un cancer | |
EA201001242A1 (ru) | ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ | |
WO2005076743A3 (fr) | Molecules de disaccharide et leurs derives et procedes d'utilisation associes | |
WO2007079164A3 (fr) | Inhibiteurs de protéines kinases | |
WO2006020060A3 (fr) | Composes de liaison aux proteines iap | |
WO2006009765A3 (fr) | Procedes d'identification et d'utilisation de composes adaptes au traitement de cellules cancereuses resistantes aux medicaments | |
WO2008133722A3 (fr) | Anticorps et diagnostics | |
WO2008064351A3 (fr) | (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8 | |
EP2476679A3 (fr) | Triazoles substitués utilisés comme inhibiteurs AXL | |
GB0525041D0 (en) | Methods, assays and compositions for treating retinol-related diseases | |
EP3311818A3 (fr) | Inhibiteurs de tyrosine-kinase de bruton pour le traitement de tumeurs solides | |
WO2009006389A3 (fr) | Composés utiles en tant qu'inhibiteurs de la kinase raf | |
WO2007086904A3 (fr) | Compositions a utiliser dans l’identification d’adenovirus | |
WO2007064872A3 (fr) | Composes de l'uree utilises dans le traitement du cancer | |
NO20076003L (no) | TGF-beta 1 spesifikke antistoffer | |
EA201001223A1 (ru) | Стабилизированные белковые композиции | |
WO2007064945A3 (fr) | Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies | |
WO2008083367A3 (fr) | Triazoles substitués par hétéroaryle polycyclique utiles comme inhibiteurs de axl | |
WO2004035747A3 (fr) | Anticorps humains neutralisant anti-ifn-$g(g) utiles comme inhibiteurs selectifs du mecanisme d'action d'ifn-gamma | |
WO2006102504A3 (fr) | Combinaisons destinees au traitement de cancer | |
BRPI0607306A2 (pt) | derivados de quinoxalina como agentes anti-tumor | |
WO2007061939A3 (fr) | Dérivés de métabolites de l'inhibiteur de hdac fk228 | |
WO2010031056A3 (fr) | Procédés et compositions pour moduler l'activité ire1, src, et abl | |
EP2631248A3 (fr) | Traitement de tumeurs à l'aide d'un anticorps anti-L1 spécifique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06816031 Country of ref document: EP Kind code of ref document: A2 |